Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)-Reference-Cited by-同舟云学术

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

Published:2012-07-07 Issue:5 Volume:62 Page:751-759
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Heinemann Volker,Vehling-Kaiser Ursula,Waldschmidt Dirk,Kettner Erika,Märten Angela,Winkelmann Cornelia,Klein Stefan,Kojouharoff Georgi,Gauler Thomas C,von Weikersthal Ludwig Fischer,Clemens Michael R,Geissler Michael,Greten Tim F,Hegewisch-Becker Susanna,Rubanov Oleg,Baake Gerold,Höhler Thomas,Ko Yon D,Jung Andreas,Neugebauer Sascha,Boeck Stefan

Publisher

BMJ

Subject

Gastroenterology

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic, predictive and clinicopathological impact of KRT81 / HNF1A- and GATA6- based transcriptional subtyping in pancreatic cancer;2024-04-30

2. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group;ESMO Open;2024-04

3. Therapie des metastasierten Pankreaskarzinoms;Springer Reference Medizin;2024

4. Signalling in pancreatic cancer: from pathways to therapy;Journal of Drug Targeting;2023-10-26

5. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?;Clinical and Translational Oncology;2023-10-04